Modus Therapeutics Holding Future Growth
Future criteria checks 0/6
Modus Therapeutics Holding's earnings are forecast to decline at 44.9% per annum. EPS is expected to decline by 43% per annum.
Key information
-44.9%
Earnings growth rate
-43.0%
EPS growth rate
Biotechs earnings growth | 42.4% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2024 | N/A | -15 | -14 | -14 | N/A |
6/30/2024 | N/A | -15 | -13 | -13 | N/A |
3/31/2024 | N/A | -15 | -14 | -14 | N/A |
12/31/2023 | N/A | -18 | -17 | -17 | N/A |
9/30/2023 | N/A | -23 | -22 | -22 | N/A |
6/30/2023 | N/A | -23 | -22 | -22 | N/A |
3/31/2023 | N/A | -21 | -21 | -21 | N/A |
12/31/2022 | N/A | -18 | -22 | -22 | N/A |
9/30/2022 | N/A | -21 | -22 | -22 | N/A |
6/30/2022 | N/A | -23 | -23 | -23 | N/A |
3/31/2022 | N/A | -22 | -22 | -22 | N/A |
12/31/2021 | N/A | -21 | -16 | -16 | N/A |
9/30/2021 | N/A | -9 | -9 | -9 | N/A |
6/30/2021 | N/A | -6 | -6 | -6 | N/A |
3/31/2021 | N/A | -5 | -5 | -5 | N/A |
12/31/2020 | N/A | -6 | -7 | -7 | N/A |
12/31/2019 | N/A | -44 | -48 | -48 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 99Z is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 99Z is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 99Z is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 99Z's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 99Z's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 99Z's Return on Equity is forecast to be high in 3 years time